<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Survival and quality of life are reported in 23 pretransfused patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (SAA) who underwent bone marrow transplantation (BMT) </plain></SENT>
<SENT sid="1" pm="."><plain>The projected survival is 76% with 18 of 23 patients being alive 332 to 1677 days post graft (median: 842) </plain></SENT>
<SENT sid="2" pm="."><plain>5 patients died between day 4 and 416 </plain></SENT>
<SENT sid="3" pm="."><plain>12 of 17 patients at risk developed <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e>-D) </plain></SENT>
<SENT sid="4" pm="."><plain>4 of these patients have a diminished quality of life due <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GVH</z:e>-D related disabling manifestations </plain></SENT>
<SENT sid="5" pm="."><plain>Autologous haemopoietic recovery was excluded in <z:hpo ids='HP_0000001'>all</z:hpo> patients by the demonstration of haemopoietic chimerism </plain></SENT>
<SENT sid="6" pm="."><plain>We recommand age-adapted rejection prophylaxis; such strategy may help to diminish disabling <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft versus host disease</z:e> in otherwise haematologically reconstituted survivors </plain></SENT>
</text></document>